Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14921953 | 0.76 | PARP1 (0.55) | PARP1ALDH1A1KDM4EMAPTKMT2A | |
| SCHEMBL5887737 | 0.75 | PARP1 (0.55) | PARP1ALDH1A1HSD17B10KDM4EMAPT | |
| SCHEMBL7083243 | 0.75 | PARP1 (0.51) | PARP1KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL5424673 | 0.73 | PIK3CD (0.54) | KMT2AMEN1 | |
| SCHEMBL10481722 | 0.70 | PIK3CD (0.50) | KMT2AMEN1 | |
| SCHEMBL5887934 | 0.69 | PARP1 (0.48) | PARP1ALDH1A1MAPT | |
| SCHEMBL7265729 | 0.69 | CYP1A2 (0.55) | KMT2AMEN1 | |
| SCHEMBL989008 | 0.68 | PIK3CD (0.52) | KMT2AMEN1 | |
| SCHEMBL19514132 | 0.68 | PIK3CD (0.52) | KMT2AMEN1 | |
| SCHEMBL31632694 | 0.68 | PIK3CD (0.52) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6649618-B2 | Prevention and/or therapy of ischaemia and reperfusion damage; poly(ADP-ribose)-synthetase inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2003-11-18 | — | — | US | disclosed |
| US-20030022905-A1 | Substituted amidoalkyl-uracils and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022905-A1 | Substituted amidoalkyl-uracils and their use | UNG, UMPS, TYMP | PARP1 283/4885ALDH1A1 158/4885HSD17B10 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.